Global Brain Corporation is a venture capital firm that invests in companies from seed or early to pre-IPO startups.  Global Brain has invested in 300+ startups from seed/early to pre-IPO startups and achieved 25 IPOs and 61 M&As as a result of providing hands-on support services and resources to its portfolio startups. Global Brain has managed a pure investment fund as well as multiple corporate venture capital funds partnered together with tier 1 public companies of telecom, real estate development, financial service, beverages, agriculture food, logistics, and electronic devices.

Global Brain Corporation

SBI Investment supports the business development and growth of private venture companies through fund investment. It manages and manages venture capital funds under the management philosophy of becoming a leading company responsible for the creation and development of core industries in the 21st century as a ''new industry creator''. SBI Investment has invested in a total of 986 companies in the past, of which 169 (17.1% of investment companies) have exited through IPO or M & A.

SBI Investment

Osaka University Venture Capital is a venture capital firm that focuses on early-stage ventures in the fields of life innovation, green innovation, and platform technology. The firm was founded in 2014 and based in Osaka, Japan.

Osaka University Venture Capital

Mitsui Mining & Smelting Company, Ltd. mainly produces non-ferrous metal such as lead and copper alloys.

Mitsui Mining & Smelting

JGC Holdings offers project management services, including resource recycling, healthcare, and life science services. They also provide energy and environmental consulting, functional material manufacturing business, gas, oil refining, chemicals, and other services.

JGC Holdings Corporation

D3 LLC is providing management consultancy and financial services.

Joyo Capital Partners

Kobe University Capital is create new indstry academia cllabration and technology transfer models.

Kobe University Capital

Alpha Fusion

Alpha Fusion produces astatine based radiopharmaceuticals for targeted alpha therapy.

Alpha Fusion Inc. is a biotechnology company focused on developing targeted alpha therapy (TAT) based on astatine-211 (211At) radiopharmaceuticals for cancer treatment. TAT involves injecting alpha-emitting radioisotopes that selectively target and destroy cancer cells in the human body. Alpha Fusion leverages research from Osaka University to advance the clinical application of astatine-211, a halogen element capable of emitting alpha particles.

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

Radioactive materials open up new pathways in patient treatment and medication

Radiopharmaceuticals

Alpha Fusion Raises Series B Funding

Alpha Fusion Inc. is a biotechnology company focused on developing targeted alpha therapy (TAT) based on astatine-211 (211At) radiopharmaceuticals for cancer treatment. TAT involves injecting alpha-emitting radioisotopes that selectively target and destroy cancer cells in the human body. Alpha Fusion leverages research from Osaka University to advance the clinical application of astatine-211, a halogen element capable of emitting alpha particles.
Astatine-211 offers several advantages over other approved radioisotopes like lutetium-177, radium-223, and iodine-131. It can be stably produced using abundant bismuth-209 and a relatively low-energy particle accelerator called a cyclotron. With a short half-life of 7.2 hours, astatine-211 allows for direct chemical formation with basic drug candidate structures designed to bind to disease target sites.
In March 2023, Sumitomo Heavy Industries invested in Alpha Fusion to support the establishment of their astatine-211 radiopharmaceutical pipeline. Sumitomo Heavy Industries contributes expertise in particle accelerators and radioisotope labeling to facilitate the development of TAT as a promising advanced cancer treatment modality.

Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, developed the first radioactive diagnostic agent approved by the US Food and Drug Administration (FDA) for imaging tau neurofibrillary tangles on positron emission tomography (PET) scans. The F-18 flortaucipir tracer, marketed under the name Tauvid, helps clinicians estimate the density and distribution of tau tangles in the brains of adults with cognitive impairment being evaluated for Alzheimer's disease.
Tauvid works by binding to tau proteins that form neurofibrillary tangles, which are a hallmark of Alzheimer's disease along with amyloid plaques. Previously, doctors could only diagnose Alzheimer's neuropathologically by identifying both plaques and tangles in the brain after death. With Tauvid, physicians can now visualize and assess tau pathology in living patients through PET imaging.
The FDA's approval of Tauvid in May 2020 was supported by two clinical studies evaluating the agent's safety and effectiveness. These studies demonstrated that readers interpreting Tauvid PET scans had a high probability of accurately detecting tau pathology and an average-to-high probability of correctly identifying patients without tau pathology.

Avid Radiopharmaceuticals

Trevarx is a biomedical company focused on developing radiopharmaceutical technologies to combat breast, ovarian, and prostate cancer. The company specializes in small molecule radiopharmaceuticals, offering a unique theranostic solution. Trevarx's approach combines therapeutic and diagnostic capabilities, potentially enhancing cancer treatment efficacy. The company leverages its expertise in scientific research and multi-center trials to advance its radiopharmaceutical technologies. Trevarx's business model includes providing support for multi-center trials, regulatory assistance, and GMP (Good Manufacturing Practice) manufacturing. These services aim to accelerate the commercialization process of their radiopharmaceutical technologies. The company's team comprises experts with extensive experience in the field, positioning Trevarx to efficiently develop and bring its solutions to market.

Trevarx Biomedical

Alpha Source is a company that manufactures and supplies alpha radiation sources, primarily composite alpha sources containing Pu-239, Am-241, and Cm-244 radionuclides electroplated onto platinum or platinum-clad nickel foils. These sources are designed for alpha spectroscopy systems, providing alpha particles in the energy range of approximately 5100 to 5800 keV with line widths typically less than 20 keV FWHM. This wide energy range allows for valid energy calibration of most alpha-emitting nuclides. Alpha Source offers its composite alpha sources in three configurations: A-1, A-2, and PM. The sources are uncovered and have an active area of 5.0 mm. When purchased as NIST traceable standards, the sources can also be used to determine detector efficiencies for alpha particles, with total and individual activities provided on the Certificate of Calibration.
In addition to its core alpha source product line, Alpha Source also provides nationwide service for extending the life of ultrasound imaging equipment through preventative maintenance and quality replacement parts. The company offers high-quality replacement parts for biomedical equipment, along with value-added services to streamline supply chain operations.
Alpha Source has over 30 years of expertise in manufacturing and sourcing high-quality medical replacement battery packs, offering solutions that optimize battery life and costs for healthcare facilities.

Alpha Source

Ionetix is a cyclotron technology and isotope manufacturing company based in the US. It developed the world's first commercial compact superconducting cyclotron, the ION-12SC, which is used to produce N-13 Ammonia, a highly accurate Positron Emission Tomography (PET) imaging agent for detecting Coronary Artery Disease (CAD). The company's proprietary cyclotron technology platform enables access to scarce radioisotopes used for diagnostic and therapeutic radiopharmaceuticals.
Ionetix's cyclotrons can produce high-purity alpha-emitting radionuclides like Actinium-225 (Ac-225) and Astatine-211 (At-211), which are utilized in targeted alpha therapies for cancer treatment. In April 2023, the company successfully produced Astatine-211 at its new Alpha Isotope Manufacturing facility in Lansing, Michigan, using a 30 MeV cyclotron. This facility is dedicated exclusively to producing alpha-emitting radionuclides via cyclotrons. In June 2024, Ionetix announced the successful production of Actinium-225, marking a pivotal milestone as the first commercial cyclotron-produced Ac-225.
Ionetix's business model involves establishing a network of ION-12SC cyclotrons installed on or near the campuses of PET programs across the US. The company covers the costs related to installation and operation, making N-13 Ammonia available to providers through a pay-by-the-dose model, ensuring accessibility and affordability. Ionetix also provides N-13, F-18, and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and "white glove" distribution logistics, enabling global access to these imaging agents and targeted radiotherapies.

Ionetix

Therapeia GmbH & Co. KG is a German specialist company focused on developing diagnostic and therapeutic radiopharmaceuticals to address unmet patient needs. Their lead product candidate, ACD-101, is a family of products for the diagnosis and treatment of malignant glioma (brain cancer). ACD-101 combines several anti-cancer effects within a single molecule, including cytostatic properties, an intrinsic radio-sensitizer effect that enhances the efficacy of external radiation therapy (the current standard treatment), and the ability to be radiolabeled with 131I for intracellular 131I-irradiation ("endo-radiotherapy"), similar to radioiodine therapy used for thyroid cancer.
ACD-101 is actively transported across the intact blood-brain barrier and accumulates in tumor tissue, where it is retained for up to a week. This intratumor accumulation occurs independently of histological tumor type in both low and high-grade gliomas (WHO grades II-IV), allowing for universal therapeutic use regardless of glioma histology. In a rat model, experimental human gliomas were curatively treated for the first time using 131I-ACD-101. This endo-radiotherapy can be combined with conventional external radiotherapy to maximize synergies of different anti-tumor modes of action.

Therapeia GmbH & Co. KG

Companies that use radioactive isotopes to develop medication for the treatment of diseases in patients.

Companies that use radioisotopes to develop solutions for the diagnosis of patients. Solutions are typically synthesized for internal use on patients and are employed in tandem with a diagnostic imaging device to identify disease or causes of diseases.

Companies that produce and supply radioisotopes to pharmaceutical companies creating radiopharmaceuticals.

Companies providing support services to radiopharmaceutical-related companies. These include testing services, research, and training.

Some drug developers use connected medical devices for monitoring treatment administration and drug development

Alpha Fusion

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless